BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma
Follows U.S. approval for relapsed or refractory marginal zone lymphoma in 2021 Third approved indication…
Follows U.S. approval for relapsed or refractory marginal zone lymphoma in 2021 Third approved indication…
KUALA LUMPUR, MALAYSIA - Media OutReach - 3 March 2022 - In support of its…
DUBLIN--(BUSINESS WIRE)--The "800V High Voltage Platform Research Report, 2022" report has been added to ResearchAndMarkets.com's…
SHENZHEN, CHINA - Media OutReach - 3 March 2022 - The OPPO Find X5 Pro…
Back Hong Kong's battle against COVID HONG KONG SAR - Media OutReach - 3 March…
Featuring approximately 1.2x processing speed and 20% less power consumption, Samsung’s LPDDR5X DRAM will boost…
SYDNEY & NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Xpansiv, the global marketplace for ESG commodities, today…
CHICAGO--(BUSINESS WIRE)--Allscripts Healthcare Solutions (NASDAQ: MDRX) (“Allscripts”) announced today that it has reached an agreement…
Quarterly revenue of $99.3 million, up 13.0% year over year Fiscal year revenue of $374.4…
SEOUL, South Korea--(BUSINESS WIRE)--Coupang, Inc. (NYSE: CPNG) today announced financial results for its fourth quarter…